Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab plus low-dose tacrolimus versus standard tacrolimus-based immunosuppression after kidney transplantation
ACTRN12610000837022Phase 3Active, not recruiting
- Sponsor
- National University Hospital
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of alemtuzumab, tacrolimus, azathioprine, prednisolone and methylprednisolone in kidney failure, sponsored by National University Hospital. Primary endpoint: Incidence of chronic lesions of interstitial fibrosis/tubular atrophy and calcineurin inhibitor nephrotoxicity on protocol biopsy. Started Feb 2011; status: active, not recruiting.
02
Drugs
alemtuzumabtacrolimusazathioprineprednisolonemethylprednisolone
03
Conditions
kidney failure
Beyond the preview
Go deeper on ACTRN12610000837022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000837022.